U.S. markets closed
  • S&P 500

    3,744.52
    -38.76 (-1.02%)
     
  • Dow 30

    29,926.94
    -346.96 (-1.15%)
     
  • Nasdaq

    11,073.31
    -75.29 (-0.68%)
     
  • Russell 2000

    1,752.51
    -10.18 (-0.58%)
     
  • Crude Oil

    88.99
    +0.54 (+0.61%)
     
  • Gold

    1,720.10
    -0.70 (-0.04%)
     
  • Silver

    20.62
    -0.03 (-0.17%)
     
  • EUR/USD

    0.9797
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    3.8260
    +0.0670 (+1.78%)
     
  • GBP/USD

    1.1159
    -0.0009 (-0.08%)
     
  • USD/JPY

    144.9070
    -0.1610 (-0.11%)
     
  • BTC-USD

    19,944.79
    -214.48 (-1.06%)
     
  • CMC Crypto 200

    456.11
    -7.01 (-1.51%)
     
  • FTSE 100

    6,997.27
    -55.35 (-0.78%)
     
  • Nikkei 225

    27,311.30
    +190.80 (+0.70%)
     

AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer

·1 min read
  • AstraZeneca plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRKannounced long-term follow-up results from the Phase 3 PAOLA-1 and SOLO-1 trials in first-line advanced ovarian cancer evaluating Lynparza (Olaparib) as a combination and monotherapy.

  • The companies said the data represents the longest-term data for any PARP inhibitor in this setting.

  • The Phase 3 PAOLA-1 trial evaluated Lynparza combined with bevacizumab as first-line maintenance therapy.

  • Final overall survival (OS) in Lynparza plus bevacizumab was 56.5 months versus 51.6 months with bevacizumab alone in newly diagnosed advanced ovarian cancer patients.

  • These OS results were not statistically significant.

  • Lynparza plus bevacizumab also improved median progression-free survival (PFS) to nearly four years (46.8 months) versus 17.6 months with bevacizumab plus placebo.

  • The Phase 3 SOLO-1 trial evaluated Lynparza as monotherapy.

  • In the trial, Lynparza demonstrated a clinically meaningful improvement in OS versus placebo in patients with germline BRCA-mutated (gBRCAm) newly diagnosed advanced ovarian cancer, reducing the risk of death by 45% versus placebo (not statistically significant).

  • Median OS was not reached with Lynparza versus 75.2 months with placebo. At the seven-year descriptive OS analysis, 67% of Lynparza patients were alive versus 47% of placebo patients.

  • Price Action: AZN shares are up 1.09% at $60.97, and MRK stock is up 0.34% at $87.71 on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.